Response to Mahe

Modern Pathology

Volumn 27, Issue 10, 2014, Pages 1424-1425

  Cooper, Wendy A ^a,b,c   Solomon, Benjamin ^d,e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

CANCER PATIENT; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; FEMALE; GENETICS; LUNG TUMOR; MALE; PROCEDURES;

ADENOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84929942764     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.58     Document Type: Letter

References (7)

1. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26:1545-1553.
2. Mahe E. Comment on 'Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization'. Mod Pathol 2014 (this issue).
3. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer correlation with fluorescence in situ hybridisation. J Thorac Oncol 2011;6:466-472.
4. Conklin C, Craddock K, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013;845-51.
5. Tsao MS, Hirsch FR, Yatabe Y (eds). IASLC Atlas of ALK Testing in Lung Cancer. International Association for the Study of Lung Cancer (IASLC): Aurora, CO, 2013.
6. Khandwala FT, Newton K, Wong D, et al. Statistics Calculator. 2004. http://ktclearinghouse.ca/cebm/toolbox/statscalc. Accessed 31 January 2013.
7. Lindeman N, Cagle P, Beasley M, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859.